Overview
My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2022 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer.
Journal Article Breast Cancer Res Treat · December 2025 PURPOSE: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), inc ... Full text Link to item CiteA comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study.
Journal Article Commun Med (Lond) · August 5, 2025 BACKGROUND: The Dallas Metastatic Cancer Study is a clinical database established to examine local trends associated with the diagnosis and treatment of de novo metastatic breast cancer and identify factors for further evaluation. Clinical characteristics ... Full text Link to item CiteA HER3-targeting antibody-drug conjugate for leptomeningeal metastasis.
Journal Article Nat Med · August 2025 Full text Link to item CiteRecent Grants
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence?A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)?
Clinical TrialPrincipal Investigator · Awarded by Stemline Therapeutics, Inc · 2025 - 2030A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician's choice chemo, for the treatment of participants with metastatic HER2-positive breast cancer
Clinical TrialPrincipal Investigator · Awarded by Jazz Pharmaceuticals · 2025 - 2030A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer with Resist...
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Boston University, School of Medicine ·
2016
M.D.